These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8615898)

  • 1. Correlation of retention of tumor methylmercaptopurine riboside-5'-phosphate with effectiveness in CD8F1 murine mammary tumor regression.
    Nord LD; Stolfi RL; Colofiore JR; Martin DS
    Biochem Pharmacol; 1996 Mar; 51(5):621-7. PubMed ID: 8615898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis induced in advanced CD8F1-murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion.
    Nord LD; Stolfi RL; Alfieri AA; Netto G; Reuter V; Sternberg SS; Colofiore JR; Koutcher JA; Martin DS
    Cancer Chemother Pharmacol; 1997; 40(5):376-84. PubMed ID: 9272113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo detection by 31P NMR of pentose phosphate pathway block secondary to biochemical modulation.
    Mahmood U; Street JC; Matei C; Ballon D; Martin DS; Koutcher JA
    NMR Biomed; 1996 May; 9(3):114-20. PubMed ID: 8892397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical modulation of tumor cell energy. IV. Evidence for the contribution of adenosine triphosphate (ATP) depletion to chemotherapeutically-induced tumor regression.
    Colofiore JR; Stolfi RL; Nord LD; Martin DS
    Biochem Pharmacol; 1995 Nov; 50(11):1943-8. PubMed ID: 8615876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marked enhancement in vivo of paclitaxel's (taxol's) tumor-regressing activity by ATP-depleting modulation.
    Martin DS; Stolfi RL; Colofiore JR; Nord LD
    Anticancer Drugs; 1996 Aug; 7(6):655-9. PubMed ID: 8913434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of chemotherapy and radiation enhancement and 31P NMR spectral changes induced by biochemical modulation.
    Koutcher JA; Alfieri AA; Tsai JC; Matei C; Stolfi RL; Ballon D; Martin DS
    Cancer Invest; 1997; 15(2):111-20. PubMed ID: 9095206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
    O'Dwyer PJ; Hudes GR; Colofiore J; Walczak J; Hoffman J; LaCreta FP; Comis RL; Martin DS; Ozols RF
    J Natl Cancer Inst; 1991 Sep; 83(17):1235-40. PubMed ID: 1714507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical modulation of tumor cell energy: regression of advanced spontaneous murine breast tumors with a 5-fluorouracil-containing drug combination.
    Stolfi RL; Colofiore JR; Nord LD; Koutcher JA; Martin DS
    Cancer Res; 1992 Aug; 52(15):4074-81. PubMed ID: 1379119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation enhancement by biochemical modulation and 5-fluorouracil.
    Koutcher JA; Alfieri AA; Thaler H; Matei C; Martin DS
    Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1145-52. PubMed ID: 9392557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer chemotherapy: past is prologue.
    Martin DS
    Mt Sinai J Med; 1985 Jun; 52(6):426-34. PubMed ID: 3875021
    [No Abstract]   [Full Text] [Related]  

  • 11. Biochemical modulation of tumor cell energy in vivo: II. A lower dose of adriamycin is required and a greater antitumor activity is induced when cellular energy is depressed.
    Martin DS; Stolfi RL; Colofiore JR; Nord LD; Sternberg S
    Cancer Invest; 1994; 12(3):296-307. PubMed ID: 8187007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer.
    Redei I; Green F; Hoffman JP; Weiner LM; Scher R; O'Dwyer PJ
    Invest New Drugs; 1994; 12(4):319-21. PubMed ID: 7775133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of a three drug chemotherapy regimen by radiation.
    Koutcher JA; Alfieri AA; Stolfi RL; Devitt ML; Colofiore JR; Nord LD; Martin DS
    Cancer Res; 1993 Aug; 53(15):3518-23. PubMed ID: 8339257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.
    Hageboutros A; Hudes GR; Brennan J; Green F; Hoffman J; LaCreta FP; Colofiore J; Martin DS; Ozols RF; O'Dwyer PJ
    Cancer Chemother Pharmacol; 1996; 37(3):229-34. PubMed ID: 8529282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced antitumor activity of an adriamycin + 5-fluorouracil combination when preceded by biochemical modulation.
    Stolfi RL; Colofiore JR; Nord LD; Martin DS
    Anticancer Drugs; 1996 Jan; 7(1):100-4. PubMed ID: 8742105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance.
    Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Casper ES; Young CW
    Cancer Res; 1983 May; 43(5):2317-21. PubMed ID: 6187448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process.
    Presta M; Rusnati M; Belleri M; Morbidelli L; Ziche M; Ribatti D
    Cancer Res; 1999 May; 59(10):2417-24. PubMed ID: 10344752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
    Erlichman C; Vidgen D
    Biochem Pharmacol; 1984 Oct; 33(20):3177-81. PubMed ID: 6487365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of L-histidinol to improve the therapeutic efficiency of 5-fluorouracil against murine breast tumors.
    Stolfi RL; Sawyer RC; Martin DS
    Cancer Res; 1987 Jan; 47(1):16-20. PubMed ID: 3791203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of the combination of 6-methylmercaptopurine riboside and 5-fluorouracil.
    Wiemann MC; Crabtree GW; Weitberg AB; Spremulli EN; Cummings FJ; Murray C; Calabresi P
    Med Oncol Tumor Pharmacother; 1988; 5(2):113-6. PubMed ID: 3412035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.